Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.

Am J Clin Dermatol · 2025 · PMC12227497 · PMID 40220208

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Mean scores demonstrated a numerical trend toward improvement from baseline (64.7 ± 18.8) to week 104 (76.7 ± 15.4), with a mean change from baseline to week 104 of 12.0 (Fig. 3 a).

also in 536 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.